CN107373664B - Composition with PM2.5 particle resistance effect - Google Patents
Composition with PM2.5 particle resistance effect Download PDFInfo
- Publication number
- CN107373664B CN107373664B CN201710588141.3A CN201710588141A CN107373664B CN 107373664 B CN107373664 B CN 107373664B CN 201710588141 A CN201710588141 A CN 201710588141A CN 107373664 B CN107373664 B CN 107373664B
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- drying
- tara
- tuckahoe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000000694 effects Effects 0.000 title abstract description 20
- 239000002245 particle Substances 0.000 title abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 61
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 claims abstract description 33
- 241000388430 Tara Species 0.000 claims abstract description 33
- 238000001035 drying Methods 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 6
- 239000013618 particulate matter Substances 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- 235000008599 Poria cocos Nutrition 0.000 claims description 33
- 244000197580 Poria cocos Species 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 23
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 16
- 230000028327 secretion Effects 0.000 abstract description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 11
- 230000008855 peristalsis Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000242 pagocytic effect Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 48
- 241000252212 Danio rerio Species 0.000 description 38
- 206010057249 Phagocytosis Diseases 0.000 description 9
- 230000008782 phagocytosis Effects 0.000 description 9
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241001098657 Pterois Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 235000007627 Caesalpinia Nutrition 0.000 description 2
- 241000522234 Caesalpinia Species 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000009372 pisciculture Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001424341 Tara spinosa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a composition with an anti-PM 2.5 particulate matter effect. The composition essentially comprises: tara extract and poria extract. The preparation method comprises the steps of adding a solvent, extracting, purifying, concentrating and drying. The composition has the effects of promoting intestinal peristalsis, improving the secretion of PM2.5 particles by intestinal tracts and enhancing the phagocytic function of macrophages on the PM2.5 particles, so that the composition can be used for preparing medicines, foods or health-care products for treating or preventing symptoms caused by the PM2.5 particles.
Description
Technical Field
The invention belongs to the field of health products, and relates to a preparation method for processing a composition by using natural plants as raw materials, in particular to a composition with an anti-haze effect. The composition of the present invention can be used as a food, a health food, or a medicine.
Background
Haze is the result of the interaction of specific climatic conditions with human activity, the main constituents of which include various solid or liquid particles or aerosols such as smoke, soot and dust. Economic and social activities of high-density population inevitably discharge a large amount of fine particulate matters (PM 2.5), once the discharge exceeds the atmospheric circulation capacity and the bearing capacity, the concentration of the fine particulate matters is continuously accumulated, and at the moment, if the discharge is influenced by quiet weather and the like, the large-scale production is extremely easy to occur. A large amount of fine particles are not only pollutants, but also carriers of harmful substances such as heavy metals, polycyclic aromatic hydrocarbons, viruses and the like, and have great influence on atmospheric visibility and climate, wherein inhalable particles can enter a respiratory system of a human body and can cause direct serious threat to the health of the human body, and the fine particles become important killers which harm the health and the life of the human body. Therefore, the preparation of the medicine which has a remarkable effect and is used for preventing or treating related symptoms caused by PM2.5 particles becomes one of hot spots in the research field of medicines or health-care foods
The invention aims to find a Chinese herbal medicine composition with better PM2.5 particle resistance effect, which takes tara and tuckahoe as raw materials. Tara (Caesalpinia spinose Kuntze), also known as Caesalpinia spinosa (Tara), is a plant of Caesalpiniaceae Caesalpinia, is mainly distributed in Peru, Ecuador, Columbia and other countries in northwest of south America, and is produced in Peru. The tara bean pods contain 53-61% of tannic acid (gallotannin), so that a supplementary raw material plant, tara, for replacing tannic acid and series products thereof is introduced from south America by resource insect research institute of China forestry scientific research institute and is planted in dry and hot, dry and warm valley areas of Yunnan province. In medicine, tannic acid is commonly used for treating pharyngolaryngitis. Poria is dried sclerotium of Wolf (Schw.) Wolf of Poria cos (Polyporaceae), has mild nature, sweet and light taste, and has effects of invigorating heart, lung, spleen and kidney meridians, and is a commonly used Chinese medicine with effects of promoting diuresis, eliminating dampness, invigorating spleen and stomach, calming heart and tranquilizing mind. It is used for treating edema, oliguria, phlegm and fluid retention, dizziness, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, and insomnia. The composition with the remarkable PM2.5 particulate matter resistance effect is prepared from the two plants through a special process, and is confirmed through a biological activity experiment.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: the invention overcomes the defects of the prior art, provides a composition of high-efficiency PM2.5 particles, and the composition can be used as food, health-care food and medicines, and also aims to provide a preparation method of the composition with the effect of resisting the PM2.5 particles, wherein the method is simple, green and environment-friendly and is suitable for large-scale production.
The invention is realized by the following technical scheme:
a composition with PM2.5 particulate matter resisting effect comprises Tara extract and Poria extract.
Preferably, the weight percentage of the tara extract is 45-95%, and the weight percentage of the tuckahoe extract is 5-55%.
More preferably, the weight percentage of tara extract is 50-90 wt%, and the weight percentage of tuckahoe extract is 10-35 wt%.
Most preferably, tara extract 88 wt%, poria cocos extract 12 wt%.
The invention also provides a preparation method of the composition with the effect of resisting PM2.5 particulate matters, which comprises the following steps: the tara extract and the tuckahoe extract are respectively prepared and then mixed according to the optimal percentage.
Preferably, the method comprises the steps of:
(1) the steps for preparing the tara extract are as follows: drying tara bean pods, mixing a certain amount of medicinal materials with water according to the mass ratio of 1: 5-1: 20, extracting for 2-3 times at the extraction temperature of at least 50 ℃, and extracting for 30-90 min each time. After extraction is finished, combining the medicinal material extracting solutions, concentrating until brix is 10-40%, and drying to obtain a light yellow tara extract, wherein the yield is not lower than 50 wt%;
(2) the preparation method of the tuckahoe extract comprises the following steps: airing and crushing the poria cocos medicinal material, mixing a certain amount of medicinal material with an ethanol solution with at least 50% volume concentration according to the mass ratio of 1: 5-1: 15, and performing reflux extraction for 2-3 times, 30-90 min each time. After extraction is finished, combining the medicinal material extracting solutions, concentrating the medicinal material extracting solutions to the relative density of 1.00-1.10 g/mL at 40 ℃, adding water with the volume being 2-5 times of that of the medicinal material extracting solutions, carrying out centrifugal filtration, and drying precipitates and filter residues to obtain a brown poria cocos extract, wherein the yield is not lower than 1.5%;
preferably, the raw material for extracting the tuckahoe extract can be fresh dried tuckahoe sclerotium, fresh dried tuckahoe peel or the mixture thereof;
preferably, the concentration method can be membrane concentration, reduced pressure concentration and normal pressure concentration;
preferably, the drying method can be spray drying, vacuum drying, heating drying, and freeze drying.
The invention also provides a composition which contains the extract composition and edible or medicinal auxiliary materials. Preferably, the composition is tablets, dispersible tablets, capsules, soft capsules, microcapsules, granules, injections, powder injections, freeze-dried powder injections, micro-pills, dropping pills, syrups, powders, extracts, soft extracts, oral liquid preparations and other formulations acceptable in the pharmaceutical or food fields.
The extract composition is used for promoting intestinal peristalsis, improving secretion of PM2.5 particulate matters by intestinal tracts and enhancing phagocytosis of PM2.5 particulate matters by macrophages.
The composition containing the extract composition is used for promoting intestinal peristalsis, improving secretion of PM2.5 particulate matters by intestinal tracts and enhancing phagocytosis of PM2.5 particulate matters by macrophages.
Application of extract composition in preparation of medicines, foods or health-care foods for preventing or treating symptoms caused by PM2.5 particles
The composition containing the extract composition is used for preparing medicines, foods or health foods for preventing or treating symptoms caused by PM2.5 particles.
Preferably, the tara extract is 46 wt%, 55 wt%, 60 wt%, 65 wt%, 70 wt%, 75 wt%, 80 wt%, 85 wt%, 90 wt%; preferably, the poria cocos extract is 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%. It will be understood by those skilled in the art that when tara extract or poria cocos extract is the respective preferred component content, the content of the other component in the composition, i.e. poria cocos extract or tara extract, can be calculated accordingly, based on the sum of the amounts of both in the composition being equal to 100 wt%.
In addition, it will be understood by those skilled in the art that if the composition contains only tara extract or poria cocos extract, the composition still has a certain efficacy against PM2.5 particles as proved by the anti-fatigue drug effect test of zebra fish. The compound preparation can promote the intestinal tract to peristalsis, improve the secretion of PM2.5 particles by the intestinal tract, and enhance the phagocytic function of macrophages on the PM2.5 particles, so that the compound preparation can be used for preparing medicines, foods or health-care foods for preventing or treating related diseases.
Drawings
FIG. 1: a phenotype diagram of the composition on the promotion of the secretion of zebra fish nano activated carbon (PM 2.5) into the intestinal tract;
FIG. 2: a phenotype graph of the composition on the promotion of intestinal peristalsis of zebra fish;
FIG. 3: the composition has a phenotype figure of promoting the phagocytic function of macrophages which phagocytose nanometer activated carbon (PM 2.5) in zebra fish bodies.
Examples
The invention is further illustrated by the following examples. It should be understood that the method described in the examples is only for illustrating the present invention and not for limiting the present invention, and that simple modifications of the preparation method of the present invention based on the concept of the present invention are within the scope of the claimed invention. All the raw materials and solvents used in the examples are commercially available products unless otherwise specified.
Preparation examples:
(1) air drying Tara pod, mixing 50kg of medicinal materials with water at a mass ratio of 1: 8, extracting at 90 deg.C for 3 times each for 80 min. After the extraction is finished, the combined medicinal material extract is concentrated under reduced pressure until brix is 30%, and then spray-dried to obtain 26.5kg of light yellow tara extract with the yield of 53 wt%.
(2) Air drying Poria (with peel and sclerotium mass ratio of 3: 7), pulverizing, mixing 70kg of medicinal materials with at least 75% ethanol solution at a mass ratio of 1: 8, and extracting under reflux for 60min for 3 times. After extraction is finished, combining the medicinal material extracting solutions, concentrating the medicinal material extracting solutions to the relative density of 1.00-1.10 g/mL at the temperature of 40 ℃, adding 2-5 times of water, carrying out centrifugal filtration, and carrying out vacuum drying on precipitates and filter residues to obtain 3.64kg of brown poria cocos extract, wherein the yield is 5.2%.
Mixing 26.5kg of tara extract and 3.64kg of tuckahoe extract uniformly to obtain a composition (batch number is Z-1), wherein the mass percentages of the extracts are as follows: 88 wt% of tara extract and 12 wt% of tuckahoe extract.
Examples of biological activity:
1 evaluation of the accelerating action of the composition on the secretion of the zebra fish nano activated carbon into the intestinal tract
Experimental animals: melanin allele mutant translucent Albino strain zebrafish, in a natural pairwise mating breeding mode. The age was 2 days after fertilization, 150 in total, and 30 in each experimental group.
Establishing an experimental model: 62.5mg/mL nano activated carbon (PM 2.5) is used as nano particles and is injected into a yolk sac of 2dpf zebra fish (equivalent to human intramuscular injection), and each zebra fish is injected with 10nL, namely a zebra fish PM2.5 secretion model is established at a dosage of 625 ng/tail.
The experimental steps are as follows: randomly selecting 150 black pigment allele mutant type semitransparent Albino strain zebra fishes 2 days (2dpf) after fertilization into a six-hole plate, treating 30 zebra fishes in each hole (experimental group), and performing intramuscular injection to give nano activated carbon to establish a zebra fish nano activated carbon secretion and intestinal function evaluation model. The composition (Z-1) was administered in water at a concentration of 62.5. mu.g/mL, while a normal control group (water-treated zebrafish for fish farming) and a model control group were set to have a volume of 3mL per well (experimental group). And (3) changing the liquid of the test sample every day, processing for 5d, counting the number (N) of zebra fish secreted into the intestinal tract by the nano activated carbon in vivo, and evaluating the influence of the test sample on the secretion of the nano activated carbon into the intestinal tract according to the statistical significance of the secretion incidence rate of the nano activated carbon. The statistical treatment result is expressed by mean + -SE, and the nano-active carbon secretion incidence calculation formula is as follows: secretion incidence (%) - (N)The nanometer active carbon is secreted into intestinal tract/NTotal number of) X 100%. The results of the experiment are shown in table 1.
TABLE 1 accelerating effect of the composition on intestinal secretion of zebra fish
As can be seen from Table 1, the tail number of the model control group zebra fish nanometer activated carbon secretion is 4/30, and the incidence rate of the nanometer activated carbon secretion is 13.3%. When the concentration of the composition is 62.5 mug/mL, the secretion tail number of the zebra fish nano activated carbon is 20/30 tails, and the secretion incidence rate of the nano activated carbon is 66.7%, which shows that the composition has the function of obviously promoting the zebra fish nano activated carbon to secrete into the intestinal tract.
2 evaluation of the accelerating action of the composition on the intestinal peristalsis of zebra fish
Experimental animals: wild type AB strain zebrafish, in a natural mated mating breeding mode. The age was 5 days after fertilization, 150 in total, and 30 in each experimental group.
Establishing an experimental model: feeding 5dpf wild AB strain zebra fish for 16h by Nile red to establish a zebra fish intestinal peristalsis model.
The experimental steps are as follows: randomly selecting wild AB strain zebra fish 5 days (5dpf) after fertilization into a culture dish, feeding the zebra fish with Nile red to establish an intestinal peristalsis model, and randomly selecting 150 models of zebra fish in a six-hole plate with 30 persons in each hole (experimental group) after the model is established. The composition (Z-1) was administered separately in water at a concentration of 62.5. mu.g/mL, while a model control group was set up with a volume of 3mL per well (experimental group). After treatment for 6 hours, 10 zebra fish are randomly selected in each experiment (concentration) group, photographed under a fluorescence microscope and data are collected, image analysis is carried out by NIS-Elements D3.10 advanced image processing software, the fluorescence intensity (S) of intestinal contents of the zebra fish is calculated, and the calculation formula of the promotion effect on the intestinal peristalsis of the zebra fish is as follows: intestinal motility promoting action (%) - (S)Model control group-STest article group)/SModel control groupX 100%. The results of the experiment are shown in table 2.
TABLE 2 promoting effect of the composition on intestinal peristalsis of zebra fish
As can be seen from Table 2, the fluorescence intensity of the zebra fish intestinal tract (Nile red) in the model control group is 1655465 pixels, while the fluorescence intensity of the zebra fish intestinal tract (Nile red) in the composition at 62.5 μ g/mL is 1379712 pixels, and the peristalsis promoting effect is 17%.
3 evaluation of the Effect of the composition on the promotion of the phagocytic function of macrophages that phagocytose Nano activated carbon (PM 2.5)
Experimental animals: melanin allele mutant translucent Albino strain zebrafish, in a natural pairwise mating breeding mode. The age was 2 days after fertilization, 180 total, 30 in each experimental group.
Establishing an experimental model: 62.5mg/mL nano activated carbon (PM 2.5) is used as nano particles and is injected into the blood circulation of 2dpf zebra fish (equivalent to human intravenous injection), 10nL of nano activated carbon is injected into each zebra fish, and the zebra fish PM2.5 phagocytosis model is established at 625 ng/tail dose.
The experimental steps are as follows: and randomly selecting 180 black pigment allele mutant type semitransparent Albino strain zebra fishes 2 days (2dpf) after fertilization in a six-hole plate, treating 30 zebra fishes in each hole (experimental group), and giving nano activated carbon for intravenous injection to establish a zebra fish nano activated carbon phagocytosis model. The concentration of the composition (Z-1) to be administered in water was 62.5. mu.g/mL, and a normal control group (water-treated zebrafish for fish farming) and a model control group were set to have a volume of 3mL per well (experimental group). Changing the liquid of the test sample every day, adding neutral red solution to perform vital body staining on the zebra fish for 16h after 2d of treatment, counting the number (N) of macrophages engulfming the nano activated carbon under a dissecting microscope after the staining is finished, and evaluating the influence of the test sample on the phagocytosis of the macrophages according to the statistical significance of the number of the macrophages engulfming the nano activated carbon. Statistical treatment results are expressed as mean ± SE, and macrophage phagocytosis promotion was calculated by the formula: macrophage phagocytosis promoting effect (%) ═ NTest article-NModel control group)/NModel control groupX 100%. The results are shown in Table 3.
TABLE 3 promoting effect of the composition on phagocytic function of macrophage of zebra fish
As shown in Table 3, the number of macrophages phagocytosing the nano activated carbon by the model control group was 11.1, while the number of macrophages phagocytosing the nano activated carbon was 21.1 and the macrophage phagocytosis promotion effects were 90% respectively at 2000. mu.g/mL of the composition, which indicates that the composition has an obvious promotion effect on the phagocytosis function of the macrophages of zebra fish.
Claims (7)
1. A composition having efficacy against PM2.5 particulate matter, characterized by: the composition comprises Tara extract and Poria extract; 45-95 wt% of tara extract and 5-55 wt% of poria cocos extract; wherein,
the steps for preparing the tara extract are as follows: drying tara bean pods, mixing a certain amount of medicinal materials with water according to a mass ratio of 1: 5-1: 20, extracting for 2-3 times at an extraction temperature of at least 50 ℃, each time for 30-90 min, after extraction is finished, combining medicinal material extracting solutions, concentrating until brix is 10-40%, and drying to obtain a light yellow tara extract, wherein the yield is not lower than 50 wt%;
the preparation method of the tuckahoe extract comprises the following steps: airing and crushing a poria cocos medicinal material, mixing a certain amount of medicinal material with an ethanol solution with at least 50% of volume concentration according to the mass ratio of 1: 5-1: 15, performing reflux extraction for 2-3 times, each time for 30-90 min, after the extraction is finished, combining medicinal material extracting solutions, concentrating to the relative density of 1.00-1.10 g/mL at 40 ℃, adding 2-5 times of water by volume, performing centrifugal filtration, and drying precipitates and filter residues to obtain a brown poria cocos extract, wherein the yield is not lower than 1.5%.
2. The composition of claim 1, wherein: 50-90 wt% of tara extract and 10-35 wt% of poria cocos extract.
3. The composition of claim 1, wherein: 88 wt% of tara extract and 12 wt% of tuckahoe extract.
4. A method for preparing a composition with efficacy against PM2.5 particulate matter according to any one of claims 1 to 3, characterized by comprising the following steps: the tara extract and the tuckahoe extract are respectively prepared and then mixed according to the percentage.
5. The method according to claim 4, characterized by comprising the steps of:
(1) the steps for preparing the tara extract are as follows: drying tara bean pods, mixing a certain amount of medicinal materials with water according to a mass ratio of 1: 5-1: 20, extracting for 2-3 times at an extraction temperature of at least 50 ℃, each time for 30-90 min, after extraction is finished, combining medicinal material extracting solutions, concentrating until brix is 10-40%, and drying to obtain a light yellow tara extract, wherein the yield is not lower than 50 wt%;
(2) the preparation method of the tuckahoe extract comprises the following steps: drying and crushing a poria cocos medicinal material, mixing a certain amount of medicinal material with an ethanol solution with at least a volume concentration of 50% according to a mass ratio of 1: 5-1: 15, performing reflux extraction for 2-3 times, each time for 30-90 min, after extraction is completed, combining medicinal material extracting solutions, concentrating to a relative density of 1.00-1.10 g/mL at 40 ℃, adding 2-5 times of water by volume, performing centrifugal filtration, and drying precipitates and filter residues to obtain a brown poria cocos extract, wherein the yield is not lower than 1.5%;
the raw material for extracting the tuckahoe extract is fresh and dried tuckahoe sclerotium, fresh and dried tuckahoe peel or the mixture of the fresh and dried tuckahoe sclerotium and the fresh and dried tuckahoe peel;
the concentration method comprises membrane concentration, reduced pressure concentration and normal pressure concentration;
the drying method comprises spray drying, vacuum drying, heating drying and freeze drying.
6. A composition comprising the composition of any one of claims 1-3 and a pharmaceutically acceptable excipient; the composition is tablets, capsules, granules, injections, powder injections, micro-pills, dropping pills, syrups, extracts, soft extracts, oral liquid preparations and other formulations acceptable in the pharmaceutical field.
7. Use of a composition according to any one of claims 1 to 3 or a composition according to claim 6 for the manufacture of a medicament for the prevention or treatment of symptoms caused by PM2.5 particulate matter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710588141.3A CN107373664B (en) | 2017-07-18 | 2017-07-18 | Composition with PM2.5 particle resistance effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710588141.3A CN107373664B (en) | 2017-07-18 | 2017-07-18 | Composition with PM2.5 particle resistance effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107373664A CN107373664A (en) | 2017-11-24 |
| CN107373664B true CN107373664B (en) | 2021-02-05 |
Family
ID=60340042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710588141.3A Active CN107373664B (en) | 2017-07-18 | 2017-07-18 | Composition with PM2.5 particle resistance effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107373664B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404560A (en) * | 2018-03-18 | 2018-08-17 | 国润生物科技（深圳）有限公司 | Remove the plant composition of PM2.5 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035051A (en) * | 1988-01-12 | 1989-08-30 | 中国医学科学院医药生物技术研究所 | A kind of manufacture method of newtype drug su-fuling |
| CN101265279A (en) * | 2008-04-29 | 2008-09-17 | 云南省化工研究院 | Method for extracting tannin from tarra bean-pod by micro-wave method |
| CN101434608A (en) * | 2008-12-12 | 2009-05-20 | 桂林莱茵生物科技股份有限公司 | Preparation of high-purity ellagic acid |
| CN103408608A (en) * | 2013-09-04 | 2013-11-27 | 云南瑞宝生物科技有限公司 | Preparation method of tala industrial tannic acid |
| CN104208107A (en) * | 2014-08-14 | 2014-12-17 | 广东省食品工业研究所 | Poria cocos extract, and preparation method and application thereof |
| CN105486786A (en) * | 2016-01-28 | 2016-04-13 | 杏辉天力（杭州）药业有限公司 | Method for detecting poria cocos triterpene compounds |
| CN105925648A (en) * | 2016-05-17 | 2016-09-07 | 杏辉天力（杭州）药业有限公司 | Tara albumen powder and polypeptide powder and production method thereof |
| CN106036898A (en) * | 2016-05-27 | 2016-10-26 | 杏辉天力（杭州）药业有限公司 | Composition having anti-fatigue effects and preparation method and use thereof |
-
2017
- 2017-07-18 CN CN201710588141.3A patent/CN107373664B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035051A (en) * | 1988-01-12 | 1989-08-30 | 中国医学科学院医药生物技术研究所 | A kind of manufacture method of newtype drug su-fuling |
| CN101265279A (en) * | 2008-04-29 | 2008-09-17 | 云南省化工研究院 | Method for extracting tannin from tarra bean-pod by micro-wave method |
| CN101434608A (en) * | 2008-12-12 | 2009-05-20 | 桂林莱茵生物科技股份有限公司 | Preparation of high-purity ellagic acid |
| CN103408608A (en) * | 2013-09-04 | 2013-11-27 | 云南瑞宝生物科技有限公司 | Preparation method of tala industrial tannic acid |
| CN104208107A (en) * | 2014-08-14 | 2014-12-17 | 广东省食品工业研究所 | Poria cocos extract, and preparation method and application thereof |
| CN105486786A (en) * | 2016-01-28 | 2016-04-13 | 杏辉天力（杭州）药业有限公司 | Method for detecting poria cocos triterpene compounds |
| CN105925648A (en) * | 2016-05-17 | 2016-09-07 | 杏辉天力（杭州）药业有限公司 | Tara albumen powder and polypeptide powder and production method thereof |
| CN106036898A (en) * | 2016-05-27 | 2016-10-26 | 杏辉天力（杭州）药业有限公司 | Composition having anti-fatigue effects and preparation method and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107373664A (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102813064B (en) | Plant extract feed additive for piglets | |
| CN103463307A (en) | Lucid ganoderma-corydalis saxicola compound chewable tablets and preparation method thereof | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN108014150B (en) | Application of natural medicine composition in preparing anti-hypoxia and anti-radiation medicine or food | |
| CN107439787B (en) | Walnut oligopeptide with PM 2.5 particle resistance effect | |
| CN107373664B (en) | Composition with PM2.5 particle resistance effect | |
| CN101732395B (en) | Medicine or health-care food composition with function of regulating immunity, preparation method and application thereof | |
| CN107361369B (en) | Chickpea extract and preparation method and application thereof | |
| CN107440114B (en) | Composition with PM2.5 particle resistance effect | |
| CN106421208B (en) | Pharmaceutical composition with chemical liver injury resistance function and preparation method thereof | |
| CN106389776B (en) | A kind of trollius chinensis granular agent and preparation method thereof | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| CN111870627A (en) | Sobering-up preparation and its preparing method and use | |
| CN112617196A (en) | Food, health-care product or pharmaceutical composition for resisting anoxia and fatigue and preparation method and application thereof | |
| CN110772552A (en) | Ginseng tablet capable of improving immunity and preparation method thereof | |
| CN109957038A (en) | A kind of preparation method of Radix Glycyrrhizae Thick many candies | |
| CN102805836B (en) | A kind of Chinese medicine composition for the treatment of primary hepatocarcinoma and preparation method thereof | |
| CN112617197A (en) | Anti-hypoxia food, health-care product or pharmaceutical composition and preparation method and application thereof | |
| CN106176901A (en) | A kind of astragalus chewable tablets and preparation method thereof | |
| CN111838666A (en) | Composition with auxiliary memory improving function and application thereof | |
| CN113018404A (en) | Blood stasis constitution health-care solid beverage and preparation method thereof | |
| CN1060663C (en) | Compound Tibet capillary artemisia patent medicine | |
| CN114796386B (en) | Composition for nourishing face and soothing nerves and preparation method thereof | |
| CN108338098A (en) | A kind of cultural method of selenium-rich bullhead | |
| CN103766500A (en) | Anti-fatigue milk tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |